Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

  title={Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.},
  author={Robert M. Grant and Javier R. Lama and Peter L Anderson and Vanessa M McMahan and Al Liu and Lorena Vargas and Pedro Goicochea and Martin Casapia and Juan Vicente Guanira-Carranza and Mar{\'i}a E Ram{\'i}rez-Cardich and Orlando Montoya-Herrera and Telmo Fern{\'a}ndez and Valdil{\'e}a Gonçalves Veloso and Susan P. Buchbinder and Suwat Chariyalertsak and Mauro Schechter and Linda-Gail Bekker and Kenneth H. Mayer and Esper Georges Kall{\'a}s and K Rivet Amico and Kathleen Mulligan and Lane R. Bushman and Robert J. Hance and Carmela Ganoza and Patricia A Defechereux and Brian S. Postle and Furong Wang and J. Jeff McConnell and Jia-Hua Zheng and Jean C. Lee and James F. Rooney and Howard S. Jaffe and Ana I. Martinez and David N. Burns and David V. Glidden},
  journal={The New England journal of medicine},
  volume={363 27},
BACKGROUND Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition. METHODS We randomly assigned 2499 HIV-seronegative men or transgender women who have sex with men to receive a combination of two oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC-TDF), or placebo once daily. All subjects received HIV testing, risk-reduction counseling, condoms, and management of sexually… 

Figures and Tables from this paper

Tenofovir-based preexposure prophylaxis for HIV infection among African women.

None of the drug regimens evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat analysis, and adherence to study drugs was low.

Preexposure prophylaxis for HIV infection among African women.

Prophylaxis with TDF-FTC did not significantly reduce the rate of HIV infection and was associated with increased rates of side effects, as compared with placebo, and drug adherence appeared to be low.

Safety and tolerability of tenofovir for preexposure prophylaxis among men who have sex with men.

  • S. Vermund
  • Medicine
    Journal of acquired immune deficiency syndromes
  • 2013
A large U.S. multi-center study of the clinical safety of daily TDF among HIV seronegative MSM, in anticipation of its use for PrEP, finds no evidence of TDF-associated renal disease was seen, compared to the placebo group.

A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective

The clinical evidence behind PrEP in women, current barriers to use afflicting this population, pharmacotherapy considerations for the female patient, alternative and future agents, and the current real-world application of PrEP are discussed.

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.

CAB-LA was superior to daily oral TDF-FTC in preventing HIV infection among MSM and transgender women and strategies are needed to prevent INSTI resistance in cases of CAB- LA PrEP failure.

Factors Associated With Discussions of Human Immunodeficiency Virus Pre-Exposure Prophylaxis in Men Who Have Sex With Men

Despite evidence that PrEP significantly reduces sexual transmission of HIV in MSM, PrEP discussions with MSM across OHS were undesirably low and additional resources need to be aimed at increasing PrEP uptake.

Renal Function and Tenofovir Disoproxil Fumarate for Preexposure Prophylaxis: How Safe Is Safe Enough?

Routine monitoring for markers of tubular damage to predict decreases in renal function is not likely to be an efficient strategy in care settings, and potential PrEP users and their clinicians should weigh carefully the benefits of its use against the potential risks of experiencing medication toxicities from daily exposure to TDF-FTC.

Maximizing Effectiveness of HIV Preexposure Prophylaxis Among Men Who Have Sex with Men

The iPrEx results suggest that low adherence may be a barrier to successful implementation of PrEP as an HIV prevention strategy among MSM, and identification of effective strategies for supporting the consistent use of prophylactic medications could provide much needed guidance in the development of interventions to support adherence to PrEP.

Oral antiretroviral chemoprophylaxis: current status

Oral chemoprophylaxis, using tenofovir and combination emtricitabine–ten ofovir, is effective for prevention of sexual HIV transmission.



Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Daily TDF-FTC prophylaxis prevented HIV infection in sexually active heterosexual adults and had a significant decline in bone mineral density, which remains unknown.

Pre-exposure chemoprophylaxis of HIV infection: quo vadis?

  • E. Clercq
  • Medicine
    Biochemical pharmacology
  • 2012

Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men

PrEP using oral FTC-TDF tablets is a robust intervention for preventing HIV acquisition among men who have sex with men, and specific drug concentrations associated with protection from HIV-1 acquisition in the iPrEx trial are estimated.

Preexposure prophylaxis for HIV infection.

FDA approval of emtricitabine/tenofovir for preexposure prophylaxis was expected, the considerations were complex and challenges exist, and it is not a panacea for HIV infection.

Considerations regarding antiretroviral chemoprophylaxis and heterosexuals in generalized epidemic settings

  • L. Paxton
  • Medicine
    Current opinion in HIV and AIDS
  • 2012
PrEP is a potentially useful HIV-prevention strategy for generalized heterosexual epidemics and Optimal implementation will require learning more about ways to improve acceptability and adherence and how best to deliver PrEP within the context of limited resource availability.

Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence

Topical tenofovir gel showed efficacy in African women and daily oral TDF and FTC/TDF were efficacious in MSM, and African HIV-1 serodiscordant couples and young heterosexuals.

HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.

Although it is unlikely to confer sufficient benefits to justify the current costs of tenofovir-emtricitabine, price reductions and/or increases in efficacy could make PrEP a cost-effective option in younger populations or populations at higher risk of infection.

Seroconversion following nonoccupational postexposure prophylaxis against HIV.

It is often impossible to determine whether seroconversion resulted from failure of PEP or from other exposures, posing difficulties for future comparative studies seeking to evaluate the effectiveness of P EP.

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Oral TDF and TDF-FTC both protect against HIV-1 infection in heterosexual men and women, and both study medications significantly reduced the HIV- 1 incidence among both men andWomen.

Behavioral Impact, Acceptability, and HIV Incidence Among Homosexual Men With Access to Postexposure Chemoprophylaxis for HIV

PEP was safe and did not appear to be associated with increases in reported high-risk behavior in this cohort, suggesting a limited public health impact of this intervention.